Veeva Systems, which sells cloud software only to drugmakers — sales and marketing systems for pharmaceutical field forces on one side, clinical-trial, regulatory and quality document management on the other — has put a price on a product that has nothing to do with drugs. On its August 26 earnings call the company described Aspen, a general-purpose customer-relationship management system billed at $50 per user per month plus usage overages, aimed first at technology startups and pitched on three-month implementations against the three-year cycles legacy systems require. Management described it as an internal startup running on small investment.

The reason a $50 seat matters at a $46bn company is what it says about the meter Veeva already owns. Commercial revenue is billed against pharmaceutical sales representatives, and that population is shrinking. US drug-company reps numbered more than 100,000 in 2005, about 12% of the industry's workforce; today they are roughly half that, 5.1% of the workforce, with more than half of all interactions with doctors now digital. Growth on that side has to come from price, modules and data rather than bodies in the field.

The half that is working is the other half

It shows in the split. Commercial subscription revenue grew 13% year on year in the quarter ended July 31 against 16% for total subscription revenue of $766.8m, and full-year guidance divides roughly $1,405m of commercial against $1,675m of research, development and quality — about 11% and 18% growth. Of the $108m of subscription revenue added year on year, $68m came from the research and development side.

That half has a visible demand source. Early-stage biotechnology funding reached $35bn in the second quarter of 2026, more than double a year earlier, and emerging biopharma now accounts for about 70% of clinical trial starts globally against 45% a decade ago — more sponsors, more studies, and Vault subscriptions bill per study and per site. IQVIA, the clinical-research and health-data company selling into the same budgets, reported a $34.2bn backlog and net new bookings of $3.15bn, up 19.3%, for a book-to-bill of 1.22.

On the commercial side the language was defensive. "We see Veeva maintaining over 70% share in the CRM space, which means we'll continue to execute," strategy chief Paul Shawah told investors on August 26. Chief executive Peter Gassner was blunter about losses: "Yes, there's a handful of customers, large customers that did select Salesforce, many of them even 2 years ago. Those projects are — they're having troubles, right?" Salesforce says its Life Sciences Cloud now has more than 140 customer organizations, roughly double a year earlier, naming Novartis, AstraZeneca, Pfizer and Takeda.

Two products, no price

Falcon, the agentic platform Veeva is building for clinical, regulatory and safety work, has five early adopters and first go-lives expected this fiscal year, with gross margins management expects to be roughly similar to software. "We are the rate limiter right now," Gassner said on the call. "We have to get that product ready, start working with the early adopters, but interest in Falcon is very high." In June Veeva bought Copli and relaunched it as Veeva Falcon MLR, claiming it can eliminate 70% or more of the manual labor in medical, legal and regulatory content review within five years. No price, no annual recurring revenue figure, no customer count beyond the five.

The shares have moved as if the price existed. Veeva gapped 14.3% on August 27 — a day the whole software complex bid up behind Salesforce's own record quarter — and pushed to $288.49 by August 31 as brokers repriced, Raymond James to $330 from $225 and RBC to $325 from $275. Trailing sales multiple has gone from about 9.2x in early May to 13.4x. Forward earnings are 31x against IQVIA's 20x, for a business consensus expects to slow from 16.4% revenue growth this year to 12.1% next.

The quarter earns some of that. Revenue rose 17.6% to $928.0m, a fourth consecutive quarter of acceleration, and operating margin widened to 29.6% from 24.8%. What the re-rating does not yet have underneath it is a second meter. Veeva sells about one year at a time — its own filing calls multi-year noncancellable obligations "not significant" — so there is no contracted cushion to point at, against Salesforce's $33.5bn of current remaining performance obligations and IQVIA's backlog. Gassner also flagged a handover inside the research franchise, from mature products like electronic trial master file and quality systems to younger ones like data capture and safety, warning that "S curves don't stack up exactly" and that it bears on next year's guidance. The company is meanwhile losing president and chief customer officer Tom Schwenger, who resigned on August 18, effective October 2, to run a long-standing Veeva partner.

The symmetry is the point. Salesforce spent the year selling into the vertical Veeva built its company on, and Veeva has answered by selling a sales system to technology startups at a price it can quote in one line.